OpGen, Inc.

Is OpGen, Inc. overvalued or undervalued?

As of August 4, 2025, OpGen, Inc. is considered undervalued with an attractive valuation grade despite significant losses and negative returns, presenting a potential investment opportunity compared to worse-performing peers.

As of 4 August 2025, OpGen, Inc. has moved from a fair to attractive valuation grade. The company appears to be undervalued, particularly given its current Price to Book Value of 15.85 and an EV to Capital Employed ratio of 27.07, despite being loss-making and having negative returns on capital and equity. In comparison, peers such as BTC Digital Ltd. and LM Funding America, Inc. exhibit significantly worse valuation metrics, with P/E ratios of -12.06 and -2.15, respectively.<BR><BR>The stock has experienced a staggering decline, with year-to-date returns of -99.98% compared to a 12.22% gain in the S&P 500, indicating a severe underperformance relative to the broader market. This dramatic drop underscores the potential for recovery, suggesting that OpGen, Inc. may present a compelling investment opportunity given its attractive valuation grade amidst a challenging performance backdrop.

Is OpGen, Inc. technically bullish or bearish?

As of September 11, 2025, OpGen, Inc. has shifted to a mildly bearish trend, indicated by a bearish MACD and moving averages, despite a bullish weekly RSI, and has significantly underperformed the S&P 500 with a year-to-date return of -99.98%.

As of 11 September 2025, the technical trend for OpGen, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish MACD on the weekly timeframe and bearish moving averages on the daily timeframe. The weekly RSI indicates bullish momentum, but the overall trend is dampened by mildly bearish signals from Bollinger Bands and KST. Additionally, the stock has significantly underperformed against the S&P 500, with a year-to-date return of -99.98% compared to the S&P 500's 12.22%.

How big is OpGen, Inc.?

As of Jun 18, OpGen, Inc. has a market capitalization of 49.13 million, with net sales of 1.27 million and a net profit of -9.40 million over the last four quarters. Shareholder's funds are -11.56 million, and total assets are 1.88 million.

As of Jun 18, OpGen, Inc. has a market capitalization of 49.13 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 1.27 million, while the sum of net profit for the same period is -9.40 million.<BR><BR>As of Dec 23, the shareholder's funds are reported at -11.56 million, and total assets amount to 1.88 million.

What does OpGen, Inc. do?

OpGen, Inc. is a precision medicine company specializing in molecular diagnostics and informatics for infectious diseases. As of September 2024, it has a market cap of $49.13 million and reported a net profit of $9 million.

Overview:<BR>OpGen, Inc. is a precision medicine company in the miscellaneous industry, focused on using molecular diagnostics and informatics to combat infectious disease.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: 9 Million (Quarterly Results - Sep 2024)<BR>- Market-cap: USD 49.13 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.43<BR>- Return on Equity: -659.91%<BR>- Price to Book: 16.45<BR><BR>Contact Details:<BR>- Address: 708 Quince Orchard Rd Ste 205, GAITHERSBURG MD: 20878-1793<BR>- Tel: ['1 240 8131260', '1 240 8131273']<BR>- Fax: 1 301 8699684<BR>- Website: http://opgen.com/

Should I buy, sell or hold OpGen, Inc.?

Who are in the management team of OpGen, Inc.?

As of March 2022, the management team of OpGen, Inc. includes Chairman William Rhodes, CEO Oliver Schacht, and Directors Mario Crovetto, Prabhavathi Fernandes, Evan Jones, and R. Donald Elsey. They oversee the company's strategic direction and operations.

As of March 2022, the management team of OpGen, Inc. includes the following individuals:<BR><BR>- Mr. William Rhodes, Chairman of the Board<BR>- Mr. Oliver Schacht, President, Chief Executive Officer, and Director<BR>- Mr. Mario Crovetto, Director<BR>- Dr. Prabhavathi Fernandes, Director<BR>- Mr. Evan Jones, Director<BR>- Mr. R. Donald Elsey, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.